ArticleNorthern clinics of Istanbul2025
Efficacy and safety of magnesium prophylaxis in children with migraine without aura.
Article in Northern clinics of Istanbul, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMigraine is one of the prevalent types of primary headache disorders in children and significantly affects their quality of life. Although pharmacological prophylaxis is often necessary, conventional treatments are frequently limited by adverse effects and modest efficacy. Magnesium, a vital intracellular cation involved in numerous neuronal and vascular functions, has been proposed as a safer alternative. However, data on its use in pediatric migraine remain limited. To investigate the effectiveness and safety profile of magnesium oxide prophylaxis in children diagnosed with migraine without aura.
methodsThis retrospective study included pediatric patients aged 7-18 years with a diagnosis of migraine without aura, treated exclusively with magnesium oxide at a dosage of 6-9 mg/kg/day or a fixed dose of 365 mg/day for four months. Headache frequency, migraine-related disability (assessed by PedMIDAS), and quality of life (measured by HIT-6) were evaluated before and after four months of prophylaxis.
resultsFollowing magnesium prophylaxis, a statistically significant reduction was observed in headache frequency, PedMIDAS scores, and HIT-6 scores (p<0.001 for all). Additionally, disability levels according to PedMIDAS grading improved significantly. No participants reported side effects during the study.
conclusionMagnesium oxide appears to be a well-tolerated, safe, and potentially effective prophylactic option for children with migraine without aura. It was associated with a significant reduction in attack frequency, disability scores, and improved quality of life. Despite promising results, the absence of a control group and serum magnesium data are notable limitations. Further prospective, randomized controlled studies are required to confirm these findings and establish the most effective dosage, duration, and formulation of magnesium for pediatric use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.